Clinical trials: Multiple Myeloma
Pancreatic Cancer, Thyroid Cancer
Integrated Cancer Repository for Cancer Research
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer…
- Conditions
- Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer
- Trial name
- iCaRe2 (NCT02012699)
- Where
- 42 sites in United States
- Volunteers
- 999,999 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Multiple Myeloma, Multiple Myeloma and Malignant Plasma Cell Neoplasms
68Ga-BCMA PET/CT in Multiple Myeloma
This is a prospective, multicenter diagnostic imaging study designed to evaluate the diagnostic accuracy and clinical utility of BCMA-targeted positron emission tomography/computed tomography (PET/CT) in patients with multiple…
- Conditions
- Multiple Myeloma, Multiple Myeloma and Malignant Plasma Cell Neoplasms, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT07319897
- Testing
- 68Ga-BCMA PET/CT
- Where
- 5 sites in China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Multiple Myeloma (MM)
PET-Enabled Dual-Energy CT in Multiple Myeloma
This pilot study will evaluate a new imaging method called PET-enabled dual-energy CT for measuring bone and soft-tissue composition in bone marrow.
- Trial name
- NCT07646873
- Testing
- PET-enabled dual-energy CT imaging, X-ray dual-energy CT imaging
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
This phase I/II trial studies how well cytokine-treated veto cells work in treating patients with hematologic malignancies following stem cell transplant.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia, Bone Marrow Failure
- Trial name
- NCT03622788
- Testing
- Anti-Thymocyte Globulin, Cyclophosphamide, Cytokine-treated Veto Cells
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Monoclonal Gammopathy of Undetermined Significance, Myeloma Multiple
Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS
No effective specific treatment is currently available for the management of Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS).
- Trial name
- GAMY (NCT06559033)
- Testing
- Evaluation of the presence and number of mutated alleles of the GBA/PSAP genes in patients with MM or MGUS
- Where
- 2 sites in France
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University Hospital, Rouen
Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM)
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
This research is testing whether the investigational drug isatuximab is safe and effective when used in combination with standard agents for the treatment of newly diagnosed multiple myeloma.
- Conditions
- Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Autologous Stem Cell Transplant
- Trial name
- NCT04653246
- Testing
- Isatuximab, Lenalidomide, Bortezomib Injection
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Jacob Laubach, MD
Neoplasms, Cancer
Cancer Experience Registry (CER) for Cancer Patients and Caregivers
The Cancer Experience Registry®: An Online Survey Research Study to Understand the Experiences of Those Impacted By a Cancer Diagnosis. The Registry is a web-based platform to distribute cross-sectional and longitudinal surveys.
- Conditions
- Neoplasms, Cancer, Caregiver
- Trial name
- CER (NCT02333604)
- Where
- United States
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Cancer Support Community, Research and Training Institute, Philadelphia
Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM)
Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution
This prospective, multicenter, observational study aims to identify molecular and immunological markers associated with disease progression in patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering…
- Conditions
- Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM), Multiple Myeloma (MM)
- Trial name
- PNRR-2022-1237 (NCT07214324)
- Testing
- Collection of biological material
- Where
- 4 sites in Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Multiple Myeloma
A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
This study assesses the impact of cannabis (also commonly called marijuana, weed, or THC) use on quality of life among patients with multiple myeloma who are receiving chemotherapy.
- Trial name
- NCT07225738
- Testing
- Non-Interventional Study
- Where
- 11 sites in United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Multiple Myeloma
A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects
The goal of this clinical study is to establish the comparability of the pharmacokinetics and similarity of the safety and immunogenicity profiles of QL2109 and Darzalex following a single intravenous infusion in healthy male…
- Trial name
- NCT07400744
- Testing
- QL2109, Darzalex
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Lymphoma, Leukemia
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
The purpose of this study is to better understand the genetic causes of Hodgkin's disease (a kind of lymphoma) and non-Hodgkin's lymphoma, as well as multiple myeloma, leukemia, and related diseases.
- Conditions
- Lymphoma, Leukemia, Multiple Myeloma, Colon Cancer
- Trial name
- NCT00582621
- Where
- 6 sites in United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain Cancer, Breast Cancer
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types.
- Conditions
- Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer
- Trial name
- CAMPERR (NCT05366881)
- Where
- 17 sites in United States
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- Adela, Inc
Kidney Transplant, Myeloma
Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults
The primary endpoint of this study is to compare the humoral response (titre and neutralizing capacity of induced antibodies) against SARS-CoV-2 following vaccination with BNT162b2 (Pfizer BioNTech) in immunocompromised persons…
- Conditions
- Kidney Transplant, Myeloma, Cancer, Hematologic Malignancy
- Trial name
- EREVA (NCT04952766)
- Testing
- Biological samples
- Where
- France
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Régional d'Orléans
Plasma Cell Myeloma
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
Primary Objectives: Safety run-in Part: To confirm the recommended dose of isatuximab when combined with lenalidomide and dexamethasone in participants with high-risk smoldering multiple myeloma (SMM) Randomized Phase 3 Part: To…
- Trial name
- NCT04270409
- Testing
- Isatuximab SAR650984, Lenalidomide, Dexamethasone
- Where
- 105 sites in United States, Australia and 22 more
- Volunteers
- 337 people, healthy volunteers welcome
- Sponsor
- Sanofi
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma
Patients with multiple myeloma experience a wide range of physical and psychological symptoms from the time of their diagnosis. Meanwhile, patients with aggressive lymphomas undergo unpredictable illness courses, resulting in…
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Multiple Myeloma Stage III, Multiple Myeloma Progression
- Trial name
- EPC-MM+L (NCT06485076)
- Testing
- Early Palliative Care
- Where
- Canada
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Multiple Myeloma
Value of Macrophage-Colony Stimulating Factor as a New Marker of Bone Lesions in Multiple Myeloma
The Primary objective of this study is to compare serum levels of Macrophage-Colony Stimulating Factor (M-CSF) in a population of patients with multiple myeloma (MM), in a population of patients with Monoclonal Gammopathy of…
- Trial name
- MCSF-MYELOME (NCT02800954)
- Testing
- blood samples, Bone marow samples
- Where
- 3 sites in France
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
Family Study of Lymphoproliferative Disorders
Blood and lymph node cancers can begin in either the lymphatic tissues (as in the case of lymphoma) or in the bone marrow (as with leukemia and myeloma), and they all are involved with the uncontrolled growth of white blood…
- Conditions
- Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Monoclonal B-Cell Lymphocytosis
- Trial name
- NCT00626496
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Multiple Myeloma
High-dose Chemotherapy+G-CSF in Peripheral Blood Stem Cell Mobilization in Patients With Multiple Myeloma
This study was a multi-center, randomized, prospective study. The purpose is to clarify that high-dose VP-16+G-CSF has better mobilization efficiency and less toxic and side effects compared with high-dose CTX+G-CSF, and minimize…
- Trial name
- NCT05517213
- Testing
- Etoposide, Cyclophosphamide
- Where
- China
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
Plasma Cell Myeloma
First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma
Primary Objectives: Dose Escalation Part A: To determine the maximum tolerated dose (MTD) of SAR442085 administered as a single agent in patients with relapsed or refractory multiple myeloma (RRMM), and determine the recommended…
- Trial name
- NCT04000282
- Testing
- SAR442085
- Where
- 12 sites in United States, Czechia and 4 more
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Sanofi
Dysglobulinemia
Familial Dysglobulinemia
Multiple Myeloma (MM) is a malignant proliferation of monoclonal plasma cells. Myeloma accounts for almost 14% of all hematologic cancers and is essentially incurable.
- Trial name
- PreFamDys (NCT02853214)
- Testing
- Genetic analysis of peripheral blood samples
- Where
- 47 sites in France
- Volunteers
- 1,868 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon